Glucose Sensors Take Field Advantage

Gluco-Chaser unveils a working prototype for non-enzymatic electrochemical glucose sensors, that reportedly offers multiple advantages over existing glucose sensors. The Gluco-Chaser CGM offers flexibility in choosing a platform format, cost savings in production and storage (highly affordable end user pricing), and other technical features that improve user comfort level and hygiene. Notable, the CGM can be used daily for extended periods of time, which is useful for management of both Type 1 and Type 2 diabetes. The glucose detection mechanism and the corresponding electrode preparation methods are proprietary.




Like this story? Subscribe to Sensors Online!

Sensors delivers a suite of newsletters, each serving as an information resource to help engineers and engineering professionals make efficient design and business decisions. Sign up to get news and updates delivered to your inbox and read on the go.


Business Benefits: Unlike most glucose sensors, CGM does not require an unstable and expensive enzyme for glucose detection. This leads to huge cost savings in production and storage of the core sensing components. Gluco-Chaser technology is applicable to various formats of glucose monitors from conventional BGM to short-term (8 ~ 48 hours)- and long-term (3 ~ 7 days, and beyond) CGMs.


Usage Benefits: CGM offers the following features: (1) calibration-free operation of the sensor*; (2) 30-minute window for initial stabilization (competitors range anywhere from 3 to 12 hrs.); and (3) affordable pricing, comparable to that of conventional finger-prick sensors. This package of features has yet to be implemented by current market leaders, making it a smarter choice for Type-2 as well as Type-1 patients.


* Currently under development


Current achievements: (1) short initial stabilization time (30 minutes); (2) long sensor stability (immersed in human plasma for 1 month); (3) animal testing (EGA A+B > 90%); (4) elimination of noise from major interferents such as ascorbic acid, acetaminophen, and maltose; (5) BGM strip sensor under development (Whole blood tested; EGA A+B = 98%; journal publication in press).


For more top-secret info, contact Peter Lee via email at either [email protected] or [email protected] or go old school and call on the phone via +1-425-625-6724.